Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. - Wikidata - awgldk - TriplyDB

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

http://www.wikidata.org/entity/Q40287836

about

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.The Role of Emerging Risk Factors in Cardiovascular Outcomes Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention Recent advances in preventing stroke recurrence.Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Evolocumab for the treatment of hypercholesterolemia.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.Cholesterol Management in the Era of PCSK9 Inhibitors.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.Emerging biologic therapies for hypercholesterolaemia.Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.PCSK9 and infection: A potentially useful or dangerous association?Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.Can LDL cholesterol be too low? Possible risks of extremely low levels.Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

P2860

Q30234302-7A1D4A68-5449-448F-B3C4-9D766763DDCD Q30234550-F784775D-7B5A-403B-AAEC-722532E892FF Q33599961-44BE679A-490C-4F32-AEC2-6D26651B7E34 Q33638980-FCAB9A6F-4D02-4427-963E-E6EA866CFB5D Q33780134-9DAAACD9-32D9-448D-A284-22424F324D4F Q33873364-CD3BD35F-5CC1-4130-8245-F3F329CF4FB1 Q33893915-7218290A-87F9-4B1D-832D-5327A2EC8E84 Q33908782-8D0FDBFF-7A56-4164-8ADC-456A793C9F5F Q36366067-CC9B9E77-CA71-45E4-9014-404FB34E37E2 Q38373507-45748F3F-64E4-4536-9B84-7D8421898AFF Q38375213-03371197-CB5F-4077-ADC4-3198C4876854 Q38604404-D9953C93-DD4C-4E6E-85FE-3D62CE00DEB8 Q38612448-53D6C758-393D-40F5-834A-89D415F807C0 Q38622565-8AB87830-A06F-4184-953F-4D5C73938998 Q38637552-9CDCA7C6-658B-4D18-AFB3-B85785EDBD06 Q38639580-2D53A57C-2EE7-4EA5-B572-467BD9B36FBA Q38641699-966D1D72-FA59-4642-8CDA-2C66ADFF8539 Q38643197-E7EAA469-C66E-4A90-8FEB-AEA499257EEA Q38646376-DE708383-522B-4F43-B24F-9902D926E304 Q38653210-A9927824-3001-45E3-A317-82F0695BDD0E Q38657213-958A73EF-9DB5-46F0-84EE-EB49843A3B0B Q38658279-C8603573-1F73-4785-924D-5F9B29E0523F Q38664321-42313171-8159-462E-B98F-8EB4B335FF30 Q38724666-EFF4C422-BDC0-43BA-A912-6922EF0385B7 Q38733149-E6D0D072-1594-4FA6-A987-0C53041B2837 Q38748867-56635A73-480C-430A-9D10-DE6EB193FCB2 Q38784846-EB5BE5F0-CB62-4E0F-BA2E-60AB8E336573 Q39179689-D60612FE-BF0B-4E64-97D0-5C83865DFE2B Q39215606-F8C15627-61F6-4512-89DD-176DBC9D9181 Q39237132-DB87D214-1170-47AC-8A4F-4E19ECD95F1B Q39324079-18C4FAD4-4743-479F-9C46-6A801445BAEF Q39333650-F82AD5CD-D021-44BF-865C-3FBF7B8F971F Q39382137-E929DF64-28EE-4F1B-B25E-0737B6C767D9 Q39393317-D408D328-80B7-48F6-AECE-86C61AF6F698 Q39440767-BF178EB5-5717-4ABC-83BF-8F9EC76C718A Q39443793-FE53EB00-CEBB-4B69-96DA-BC67AFCEC5E8 Q39453691-E3311325-51D0-4369-980D-C711469B5A3D Q39458225-6043C2AA-4BC0-4DE1-9A20-2976AFD8ED92 Q40069909-3A34B7F5-A129-4CBB-9731-3FD82E89E672 Q40100018-091E2394-2068-45D6-9DB5-7C95EF686798

P2860

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

http://www.wikidata.org/entity/Q40287836

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

@en

type

label

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

@en

prefLabel

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

@en

P1433

Q40287836-50ED473B-DAE3-44DE-BBB7-D014BBE810C4

P1476

Q40287836-7257162E-A66C-4E0F-98AF-56FBDD492743

P2093

Q40287836-03587CD0-3E25-4E6A-A641-889D8F68F477

Q40287836-04A6D5AD-123D-4725-9BAB-96F8E7CE72A8

Q40287836-3596F681-22D7-4519-909C-D6DC2EA5DB9B

Q40287836-39CF5A2D-2C05-43E5-9921-DCB1015E9554

Q40287836-45CD1F3A-A043-4613-AA44-DC99ADFE8C29

Q40287836-5283EB11-0F29-4E3A-80F1-77AD4441D401

Q40287836-57F1977A-BBB8-4FBE-B27B-512F9FDF957C

Q40287836-64467111-28B5-4867-95AE-D4BCF12BDE27

Q40287836-6FF9D95F-B721-493D-A316-9D96B3E1F1E8

Q40287836-95472DFD-9999-485C-A0D9-FCF2DB0358B6

P304

Q40287836-3CD800E2-2574-4BA7-ADBA-7D5D71C99F0F

P31

Q40287836-1620666A-2245-480E-905B-3933C2AF7F4F

P356

Q40287836-53981030-18B4-4E8E-BFAB-C3645C564DB4

P407

Q40287836-87158E77-8E38-43D4-8953-F6C69C772446

P433

Q40287836-D1A55AB8-6744-4ED9-BC6B-E0F3B23C548F

P478

Q40287836-39CFA4A5-DBA6-440A-910C-F358162DE492

P50

Q40287836-008373D3-3377-4632-93E3-77532837078C

P577

Q40287836-96659637-B8DB-48F6-8DE5-67D672F61F83

P698

Q40287836-49A12596-81F8-478B-8DE7-EB888D7A468E

P921

Q40287836-5DFAEAEB-9C0D-45C1-9A5B-88CFE7FDBE7E

P356

P1433

The New England Journal of Medicine

P1476

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

@en

P2093

Anthony C Keech

http://www.w3.org/2001/XMLSchema#string

FOURIER Steering Committee and Investigators

http://www.w3.org/2001/XMLSchema#string

Huei Wang

http://www.w3.org/2001/XMLSchema#string

Julia F Kuder

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

Narimon Honarpour

http://www.w3.org/2001/XMLSchema#string

Peter S Sever

http://www.w3.org/2001/XMLSchema#string

Sabina A Murphy

http://www.w3.org/2001/XMLSchema#string

Scott M Wasserman

http://www.w3.org/2001/XMLSchema#string

Stephen D Wiviott

http://www.w3.org/2001/XMLSchema#string

P304

1713-1722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1615664

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

Robert P Giugliano

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28304224

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease